Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Bailey Sue
   2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
400 PROFESSIONAL DR, SUITE 400		 3. Date of Earliest Transaction (Month/Day/Year)
01/17/2017
(Street)

GAITHERSBURG, MD 20879		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 08/01/2016   J   152 A $ 0 34,637 D  
Common Stock (2) 08/01/2016   J   604 A $ 0 35,241 D  
Common Stock (3) 08/01/2016   J   577 A $ 0 35,818 D  
Common Stock 01/17/2017   M   3,157 (4) A $ 10.64 38,975 D  
Common Stock 01/17/2017   S   3,157 (4) D $ 29.7789 (5) 35,818 D  
Common Stock 01/17/2017   M   3,157 (4) A $ 14.71 38,975 D  
Common Stock 01/17/2017   S   3,157 (4) D $ 29.7789 (5) 35,818 D  
Common Stock 01/17/2017   M   3,157 (4) A $ 20.08 38,975 D  
Common Stock 01/17/2017   S   3,157 (4) D $ 29.7789 (5) 35,818 D  
Common Stock 01/17/2017   M   4,735 (4) A $ 13.37 40,553 D  
Common Stock 01/17/2017   S   4,735 (4) D $ 29.7789 (5) 35,818 D  
Common Stock 01/17/2017   M   3,157 (4) A $ 13 38,975 D  
Common Stock 01/17/2017   S   3,157 (4) D $ 29.7789 (5) 35,818 D  
Common Stock 01/17/2017   M   2,061 (4) A $ 18.64 37,879 D  
Common Stock 01/17/2017   S   2,061 (4) D $ 29.7789 35,818 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) (6) $ 10.64 08/01/2016   J   277     (8) 05/20/2019 Common Stock 277 $ 0 3,157 D  
Stock Option (Right to buy) (7) $ 10.64 01/17/2017   M(4)     3,157   (8) 05/20/2019 Common Stock 3,157 $ 0 0 D  
Stock Option (Right to buy) (6) $ 14.71 08/01/2016   J   277     (8) 05/19/2020 Common Stock 277 $ 0 3,157 D  
Stock Option (Right to buy) (7) $ 14.71 01/17/2017   M(4)     3,157   (8) 05/19/2020 Common Stock 3,157 $ 0 0 D  
Stock Option (Right to buy) (6) $ 20.08 08/01/2016   J   416     (8) 05/18/2021 Common Stock 416 $ 0 4,736 D  
Stock Option (Right to buy) (7) $ 20.08 01/17/2017   M(4)     3,157   (8) 05/18/2021 Common Stock 3,157 $ 0 1,579 D  
Stock Option (Right to buy) (6) $ 13.37 08/01/2016   J   693     (8) 05/16/2019 Common Stock 693 $ 0 7,893 D  
Stock Option (Right to buy) (7) $ 13.37 01/17/2017   M(4)     4,735   (8) 05/16/2019 Common Stock 4,735 $ 0 3,158 D  
Stock Option (Right to buy) (6) $ 13 08/01/2016   J   693     (8) 05/22/2020 Common Stock 693 $ 0 7,893 D  
Stock Option (Right to buy) (7) $ 13 01/17/2017   M(4)     3,157   (8) 05/22/2020 Common Stock 3,157 $ 0 4,736 D  
Stock Option (Right to buy) (6) $ 18.64 08/01/2016   J   905     (8) 05/21/2021 Common Stock 905 $ 0 10,305 D  
Stock Option (Right to buy) (7) $ 18.64 01/17/2017   M(4)     2,061   (8) 05/21/2021 Common Stock 2,061 $ 0 8,244 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Bailey Sue
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG, MD 20879		   X      

Signatures

 /s/ Eric Burt, Attorney-in-fact   01/19/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017.
(2) In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018.
(3) In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019.
(4) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey.
(5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive.
(6) In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant.
(7) Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off.
(8) The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.